Leveragen, Inc., a Boston-based early-stage biotech company developing next-generation genetic models for antibody discovery, announced today that it has entered into a multi-target commercial license agreement with 92Bio, Inc., a biotech firm focused on the development of therapeutic antibodies. This strategic collaboration utilizes Leveragen's proprietary Singularity Sapiens Mouse platform, a state-of-the-art technology for identifying and developing fully human single-domain antibodies, to facilitate the creation of multi-specific antibodies and other advanced therapeutics....